phosphonoacetic acid has been researched along with Experimental Neoplasms in 22 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 7.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 3.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "Cyclin D1 is a key regulator of the G1-S transition in cell cycle, and its gene is amplified and overexpressed in many cancers." | 1.29 | Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells. ( Asano, K; Kakizoe, T; Machida, T; Ochiya, T; Ohishi, Y; Sakamoto, H; Sasaki, H; Sugimura, T; Terada, M; Yoshida, T, 1995) |
| "Both normal and colonic cancer cells, when cultured in the presence of these agents, cease to increase their cell numbers." | 1.26 | Antiproliferative agents and differential survival between normal and cancer cells. ( Kwong, LK; Tsuboi, KK, 1978) |
| "Another solid tumor, Ridgway osteogenic sarcoma, which is sensitivie to many established chemotherapeutic agents, did not respond to PALA." | 1.26 | Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. ( Goldin, A; Inouye, T; Johnson, RK; Stark, GR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (77.27) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, S | 1 |
| Deckter, LA | 1 |
| Kasai, K | 1 |
| Chiocca, EA | 1 |
| Saeki, Y | 1 |
| Kensler, TW | 3 |
| Jayaram, HN | 4 |
| Cooney, DA | 5 |
| Erlichman, C | 1 |
| Rozencweig, M | 2 |
| Abele, R | 1 |
| Piccart, M | 1 |
| Von Hoff, DD | 2 |
| Muggia, FM | 2 |
| Mutter, G | 1 |
| Hankerson, JG | 1 |
| Reck, LJ | 2 |
| Harley, C | 1 |
| Han, N | 1 |
| Ardalan, B | 1 |
| Cysyk, RL | 2 |
| Johnson, RK | 6 |
| Vatteroni, L | 1 |
| Piras, A | 1 |
| Mariani, T | 1 |
| Caligo, MA | 1 |
| Rainaldi, G | 1 |
| Koutcher, JA | 1 |
| Alfieri, AA | 1 |
| Stolfi, RL | 1 |
| Devitt, ML | 1 |
| Colofiore, JR | 1 |
| Nord, LD | 1 |
| Martin, DS | 1 |
| Asano, K | 1 |
| Sakamoto, H | 1 |
| Sasaki, H | 1 |
| Ochiya, T | 1 |
| Yoshida, T | 1 |
| Ohishi, Y | 1 |
| Machida, T | 1 |
| Kakizoe, T | 1 |
| Sugimura, T | 1 |
| Terada, M | 1 |
| Osieka, R | 1 |
| Houchens, DP | 1 |
| Goldin, A | 2 |
| Moyer, JD | 1 |
| Handschumacher, RE | 1 |
| Vistica, DT | 1 |
| Kariya, S | 1 |
| Swyryd, EA | 1 |
| Stark, GR | 2 |
| Tsuboi, KK | 2 |
| Kwong, LK | 2 |
| Edmunds, NH | 1 |
| Inouye, T | 1 |
| O'Dwyer, PJ | 3 |
| King, SA | 1 |
| Hoth, DF | 1 |
| Leyland-Jones, B | 2 |
4 reviews available for phosphonoacetic acid and Experimental Neoplasms
| Article | Year |
|---|---|
m-AMSA and PALA: two new agents in cancer chemotherapy.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Aspartic Acid; Cell Division; Kinetics; Neoplasms, E | 1979 |
The role of low-dose PALA in biochemical modulation.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Clinical Trials as Topic; Dose-Response Relationship, | 1990 |
Role of thymidine in biochemical modulation: a review.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1987 |
Biochemical modulation: application of laboratory models to the clinic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cytarabine; Dose-Response Re | 1986 |
18 other studies available for phosphonoacetic acid and Experimental Neoplasms
| Article | Year |
|---|---|
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Gene Expression; Genetic Engineering; Ge | 2006 |
Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hyd | 1982 |
An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartic Acid; Drug Evaluation; Humans; Kinetics; Neoplasm | 1980 |
N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Drug Evalua | 1980 |
Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Topics: Amides; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carcinoma; Cell Line; Dose-Response | 1981 |
Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydr | 1981 |
Accumulation of anchorage independent cells showing amplified genes (CAD) during the in vitro propagation of CHEF18 Chinese hamster cells.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydr | 1993 |
Potentiation of a three drug chemotherapy regimen by radiation.
Topics: 6-Aminonicotinamide; Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combine | 1993 |
Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells.
Topics: 3T3 Cells; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glu | 1995 |
Analogs of L-aspartic acid in chemotherapy for cancer.
Topics: Adenylosuccinate Synthase; Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartate | 1979 |
Chemotherapy of human colon cancer xenografts in athymic nude mice.
Topics: Acridines; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma | 1977 |
Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartic Acid; Cells, Cultured; Female; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred | 1979 |
Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Biological Transport; Drug Resistance; Femal | 1979 |
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Cells, Cult | 1978 |
Antiproliferative agents and differential survival between normal and cancer cells.
Topics: Adenocarcinoma; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasm | 1978 |
Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Body Weight; Carbamates; Lung Neoplasms; Male; Mice; | 1977 |
Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
Topics: Animals; Aspartic Acid; Cell Division; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Humans; Ki | 1977 |
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; D | 1976 |